Trial Shows Interactions Between KRAS Mutations, Erlotinib Therapy in NSCLC
A trial showed that KRAS wild-type NSCLC patients fare better with regimens containing erlotinib, while KRAS-mutated patients had better outcomes without erlotinib.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news